Definitely. Accelerated Approval was coming in late 2012 / early 2013 and CSM is entirely responsible for bavituximab market delay which is counted in YEARS. $2 billion suddenly doesn't look like a big sum to ask.
All true? "No more doubt about approval". Is that true? Why is the pps $1.40? You would think it would be much higher if there were no more doubt about approval. Could this be cp's opinion?
Market Data 
Markets 
